BRAFV600E and BRAF-inactivating mutations in NSCLC
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference10 articles.
1. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer;Lin;Proc Natl Acad Sci USA,2014
2. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial;Planchard;Lancet Oncol,2016
3. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial;Planchard;Lancet Oncol,2016
4. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol,2017
5. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer;Xue;Nat Med,2017
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. High Wnt2 Expression Confers Poor Prognosis in Colorectal Cancer, and Represents a Novel Therapeutic Target in BRAF-Mutated Colorectal Cancer;Medicina;2023-06-12
2. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer;Molecular Biomedicine;2022-12-12
3. Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments;Current Treatment Options in Oncology;2021-06-10
4. CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition;Oncogene;2019-07-08
5. Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway;EBioMedicine;2019-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3